Skip to content
          • Log In
      Drug Discovery World (DDW)Drug Discovery World (DDW)
        • About Us
        • Subscribe Free
        • Media Info
        • Contact Us
          Drug Discovery World (DDW) Menu   ≡ ╳
          • Home
          • News
          • Exclusive Content
            • Features
            • Opinion
            • Market Reports
            • Trends & Analysis
            • Start-up Zone
          • DDW eBooks & eReports
          • Cancer Research
          • Business
          • Regulatory
          • Events
          • Webinars
          • Resources
          • Archive
            • –
              • 2000 Archive
              • 2001 Archive
              • 2002 Archive
              • 2003 Archive
              • 2004 Archive
              • 2005 Archive
              • 2006 Archive
            • –
              • 2007 Archive
              • 2008 Archive
              • 2009 Archive
              • 2010 Archive
              • 2011 Archive
              • 2012 Archive
              • 2013 Archive
            • –
              • 2014 Archive
              • 2015 Archive
              • 2016 Archive
              • 2017 Archive
              • 2018 Archive
              • 2019 Archive
          • Multimedia
            • Videos
            • Podcasts

          Sidebar Banner 6

          Sidebar Banner 7

          Sidebar Banner 8

          Sidebar Banner 12

          Sidebar Banner 18

          Sidebar Banner 19

          Sidebar Banner 20

          Sidebar Banner 21

        Minoryx Therapeutics

        ""

        FDA approves Phase III cerebral Adrenoleukodystrophy trial

        12 June 2023

        The US Food and Drug Administration (FDA) has approved Minoryx Therapeutics’ Phase III clinical trial (CALYX) of leriglitazone, to treat adult male X-linked Adrenoleukodystrophy (X-ALD) patients with cerebral Adrenoleukodystrophy (cALD). Patient recruitment is expected to start by the end of Q2 2023 with results anticipated by late 2025. Marc Martinell, CEO of Minoryx, said: “CALYX […]

        MRI of the brain

        New treatment slows progression of neurodegenerative disease

        16 February 2023

        Minoryx Therapeutics has revealed the findings from the first and largest international study to enroll adult male X-linked adrenoleukodystrophy patients.  The Phase II/III ADVANCE clinical trial of lead candidate, leriglitazone, published in The Lancet Neurology, did not meet the primary outcome for the six-minute walk test.   However, clinical measures of body sway (assessing balance) demonstrated […]

        Sidebar Banner 1

        Sidebar Banner 2

        Sidebar Banner 3

        Sidebar Banner 4

        Sidebar Banner 9

        Sidebar Banner 10

        Sidebar Banner 11

        Sidebar Banner 13

        Sidebar Banner 14

        Sidebar Banner 15

        Sidebar Banner 16

        Sidebar Banner 17

          • Contact Us
          • About Us
          • Subscribe FREE
          • Media Info
          • Log In
          • Terms and Conditions
          • Privacy Policy
          • Cookie Policy

        Follow our social accounts

             

        Copyright 2023 © Drug Discovery World (DDW). All Rights Reserved

        Designed & Developed with ❤ for digital by Inbound FinTech

        • Home
        • News
        • Exclusive Content
          • Features
          • Market Reports
          • Opinion
          • Trends & Analysis
          • Start-up Zone
        • DDW eBooks & eReports
        • Cancer Research
        • Business
        • Regulatory
        • Events
        • Webinars
        • Resources
        • Archive
        • Multimedia
          • Podcasts
          • Videos
        • About Us
        • Subscribe Free
        • Media Info
        • Contact Us
            • Log In